Table 2

Clinical presentation and radiological features of antiphospholipid antibody-associated chorea

PUMCH
(n=13)
Literature
(n=167)
Overall
(n=180)
Episodes
=19/12 (75)111/167 (66.5)120/179 (67.0)
>13/12 (25)56/167 (33.5)59/179 (33.0)
Mean (range)1.2 (1, 2)1.5 (1, 6)1.5 (1, 6)
Localisation
Unilateral or bilateral
 Bilateral8/12 (66.7)86/148 (58.1)94/160 (58.8)
 Unilateral4/12 (33.3)62/148 (41.9)66/160 (37.5)
Upper limb, lower limb, both
 Both10/12 (83.3)92/105 (87.6)102/117 (87.2)
 Upper limb2/12 (16.7)13/105 (12.4)15/117 (12.8)
 Lower limb0/12 (0)0/105 (0)0/117 (0)
Head or face involvement9/12 (75)74/102 (72.5)83/114 (72.8)
Precipitating factors
Oral contraceptive0/12 (0)14/167 (8.4)14/179 (7.8)
Pregnancy1/12 (8.3)12/167 (7.2)13/179 (7.3)
None10/12 (83.3)139/167 (83.2)149/179 (83.2)
Duration from onset to improvement
Days0/12 (0)2/154 (1.3)2/166 (1.2)
Weeks0/12 (0)30/154 (19.5)30/166 (18.1)
Months12/12 (100)85/154 (55.2)97/166 (58.4)
Years0/12 (0)37/154 (24.0)37/166 (22.3)
Duration of follow-up, months
Median (range)24.9 (3.1, 97.1)18 (0.2, 588)22.8 (0.2, 588)
MRI
Availability11/13 (84.6)124/167 (74.3)135/180 (75.0)
Abnormality7/11 (63.6)58/124 (46.8)65/135 (48.1)
Basal ganglia lesions1/7 (14.3)19/58 (32.8)20/65 (30.8)
White matter hyperintensities5/7 (71.4)25/42 (59.5)30/49 (61.2)
Atrophy0/7 (0)4/42 (9.5)4/49 (8.2)
PET-CT/MRI
Availability5/13 (38.5)11/167 (6.6)16/180 (8.9)
Abnormality5/5 (100.0)11/11 (100.0)16/16 (100.0)
Hypermetabolism of basal ganglia5/5 (100.0)11/11 (100.0)16/16 (100.0)
Hypometabolism of other regions3/5 (60.0)3/11 (27.3)6/16 (37.5)
Repeat in complete remission1/5 (20.0)5/11 (45.5)6/16 (37.5)
Back to normal1/1 (100.0)5/5 (100.0)6/6 (100.0)
  • PET, positron emission tomography; PUMCH, Peking Union Medical College Hospital.